시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비방사선 척추축 관절염 치료제 시장 보고서(2025년)
Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025
상품코드 : 1769680
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비방사선학적 척추축 관절염 치료제 시장 규모는 앞으로 수년간 급성장할 것으로 예측됩니다. 예측 기간 동안의 예상 성장은 이 질환에 대한 인식의 제고 및 조기 발견, 바이오시밀러의 확산, 생물학적 의약품의 지속적인 개선 및 향후 치료 혁신, R&D에 대한 관심 증가, 표적화 및 개인 맞춤형 치료 전략의 채택 증가, 의료 인프라의 발전과 관련이 있습니다. 이 기간 동안 예상되는 주요 트렌드로는 개인 맞춤형 치료 방법의 개발, 진단에 디지털 도구의 사용, 목표에 맞춘 치료 전략에 대한 선호도 증가, 가치 기반 가격 책정 체계의 구현, 그리고 다분야 관리 모델의 광범위한 채택 등이 있습니다.

임상 시험의 수가 증가함에 따라 비방사선 척추축 관절염 치료제 시장의 성장이 가속화될 것으로 예상됩니다. 인간을 대상으로 진행하는 연구인 임상 시험은 의료 치료 또는 중재의 안전성, 효과 및 부작용을 평가하는 데 필수적입니다. 임상 시험의 증가는 안전성과 효능을 보장하기 위해 엄격한 테스트가 필요한 개인 맞춤형의 혁신적인 치료법에 대한 수요가 증가함에 따라 크게 촉진되고 있습니다. 이러한 임상 시험은 질병의 초기 단계에서 치료의 효과와 안전성을 증거 기반으로 검증하며, 이는 비방사선 척추축 관절염 치료제의 규제 승인 및 임상 채택을 안내하는 데 매우 중요합니다. 예를 들어, 2023년 11월, 영국에 본사를 둔 무역 협회인 영국 제약 산업 협회(Association of the British Pharmaceutical Industry)는 영국에서 산업 임상 시험에 대한 연간 모집이 15% 증가했으며, 참가자 수는 2021-22년 3만 6,722명에서 2022-23년 4만 2,088명으로 증가했다고 보고했습니다. 이러한 동향은 임상 시험의 수가 증가하면서 시장 확장에 크게 기여하고 있음을 나타냅니다.

비방사선 척추축 관절염(nr-axSpA) 치료제 시장에서 활동하는 기업들은 시장 입지를 확대하고, 신약 출시 시간을 단축하며, 경쟁 우위를 확보하기 위해 규제 당국의 승인을 확보하는 데 점점 더 집중하고 있습니다. 규제 당국의 승인은 정부 기관의 공식적인 승인을 의미하며, 의약품이나 치료법의 안전성, 유효성 및 표준 준수 여부가 확인되면 법적으로 판매 및 처방이 가능해집니다. 예를 들어, 2022년 10월 미국 바이오제약 기업 AbbVie Inc.는 TNF 억제제에 충분히 반응하지 않은 활동성 비방사선 척추축 관절염을 앓는 성인 환자를 대상으로 Rinvoq(upadacitinib)에 대한 FDA 승인을 받았습니다. 이 승인은 Rinvoq의 미국 내 6번째 적응증이며, nr-axSpA 치료를 위한 첫 번째이자 유일한 경구용 JAK 억제제로 승인되었습니다. 이 결정은 SELECT-AXIS 2 임상 시험 결과에 기반했으며, Rinvoq를 투여받은 환자의 약 절반이 14주 후 질병 활동도가 위약군 대비 유의미하게 개선되었습니다. 이 승인은 이 어려운 질환에 직면한 환자에게 새로운 1일 1회 경구 치료 옵션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Non-radiographic axial spondyloarthritis therapeutics refer to treatments designed to manage symptoms and slow disease progression in individuals who do not exhibit visible joint damage on X-rays. These therapies primarily include non-steroidal anti-inflammatory drugs (NSAIDs), biologic treatments such as TNF and IL-17 inhibitors, and JAK inhibitors. The primary objectives are to alleviate inflammation, enhance physical function, and prevent the emergence of radiographic changes in the spine and joints.

The key categories of non-radiographic axial spondyloarthritis therapies include non-steroidal anti-inflammatory drugs, biologics, small molecule treatments, and corticosteroids. NSAIDs help reduce inflammation, pain, and fever by blocking enzymes involved in the production of prostaglandins. These drugs can be administered through oral, injectable, and topical methods and are utilized across various settings, including hospitals, ambulatory surgical centers, and homecare environments.

The non-radiographic axial spondyloarthritis therapeutic market research report is one of a series of new reports from The Business Research Company that provides non-radiographic axial spondyloarthritis therapeutic market statistics, including non-radiographic axial spondyloarthritis therapeutic industry global market size, regional shares, competitors with a non-radiographic axial spondyloarthritis therapeutic market share, detailed non-radiographic axial spondyloarthritis therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the non-radiographic axial spondyloarthritis therapeutic industry. This non-radiographic axial spondyloarthritis therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-radiographic axial spondyloarthritis therapeutics market size has grown rapidly in recent years. It will grow from $0.93 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period is due to various factors such as an increase in the prevalence of axial spondyloarthritis, rising disease awareness, a growing patient population, expanding adoption of biologic therapies, and heightened research and development efforts.

The non-radiographic axial spondyloarthritis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.55 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during the forecast period can be linked to the rising awareness and early detection of the condition, proliferation of biosimilars, continuous improvements in biologic drugs and upcoming treatment innovations, increasing focus on R&D, a higher uptake of targeted and personalized treatment strategies, and advancements in healthcare infrastructure. Prominent trends expected during this period include development of personalized therapeutic approaches, use of digital tools for diagnosis, a growing preference for treat-to-target strategies, implementation of value-based pricing frameworks, and broader adoption of multidisciplinary management models.

The increasing number of clinical trials is expected to propel the growth of the non-radiographic axial spondyloarthritis therapeutic market. Clinical trials, which are research studies conducted on humans, are essential for evaluating the safety, effectiveness, and side effects of medical treatments or interventions. The rise in clinical trials is largely driven by the growing demand for personalized and innovative treatments that require rigorous testing to ensure safety and efficacy. These trials provide evidence-based validation of treatment effectiveness and safety in early-stage disease, which is critical for guiding regulatory approvals and clinical adoption of non-radiographic axial spondyloarthritis therapeutics. For example, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported a 15% increase in annual recruitment to industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. This trend indicates that the growing number of clinical trials is significantly contributing to market expansion.

Companies operating in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market are increasingly focusing on securing regulatory approvals to broaden their market presence, reduce time-to-market for new therapies, and gain a competitive edge. Regulatory approvals involve official authorization from government agencies, allowing drugs or therapies to be legally marketed and prescribed once their safety, efficacy, and compliance with standards have been verified. For instance, in October 2022, AbbVie Inc., a US-based biopharmaceutical company, received FDA approval for Rinvoq (upadacitinib) to treat adults with active non-radiographic axial spondyloarthritis who have objective signs of inflammation and have not responded adequately to TNF inhibitors. This approval marks the sixth U.S. indication for Rinvoq and makes it the first and only oral JAK inhibitor approved for nr-axSpA. The decision was based on results from the SELECT-AXIS 2 clinical trial, which showed that nearly half of the patients treated with Rinvoq experienced significant improvements in disease activity at 14 weeks compared to those receiving a placebo. This approval offers a new once-daily oral treatment option for patients facing this challenging condition.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics for an undisclosed sum. The acquisition aims to bolster Eli Lilly's immunology portfolio by integrating DICE's promising oral IL-17 inhibitors for autoimmune diseases. This move enhances Eli Lilly's capacity to address chronic inflammatory conditions with innovative and patient-friendly oral therapies. DICE Therapeutics, a US-based biopharmaceutical company, is known for its oral IL-17 antagonists, including DC-806 and DC-853, developed for treating non-radiographic axial spondyloarthritis and other autoimmune diseases.

Major players in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc., Johnson & Johnson, Allergan plc, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Mochida Pharmaceutical Co. Ltd., Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co. Ltd., and Qyuns Therapeutics Co. Ltd.

North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2024. The regions covered in non-radiographic axial spondyloarthritis therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-radiographic axial spondyloarthritis therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-radiographic axial spondyloarthritis therapeutic market consists of sales of TNF inhibitors, JAK inhibitors, non-steroidal anti-inflammatory drugs, and IL-23 inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-radiographic axial spondyloarthritis therapeutic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for non-radiographic axial spondyloarthritis therapeutic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-radiographic axial spondyloarthritis therapeutic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Characteristics

3. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Trends And Strategies

4. Non-Radiographic Axial Spondyloarthritis Therapeutic Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Growth Analysis And Strategic Analysis Framework

6. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Segmentation

7. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Regional And Country Analysis

8. Asia-Pacific Non-Radiographic Axial Spondyloarthritis Therapeutic Market

9. China Non-Radiographic Axial Spondyloarthritis Therapeutic Market

10. India Non-Radiographic Axial Spondyloarthritis Therapeutic Market

11. Japan Non-Radiographic Axial Spondyloarthritis Therapeutic Market

12. Australia Non-Radiographic Axial Spondyloarthritis Therapeutic Market

13. Indonesia Non-Radiographic Axial Spondyloarthritis Therapeutic Market

14. South Korea Non-Radiographic Axial Spondyloarthritis Therapeutic Market

15. Western Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market

16. UK Non-Radiographic Axial Spondyloarthritis Therapeutic Market

17. Germany Non-Radiographic Axial Spondyloarthritis Therapeutic Market

18. France Non-Radiographic Axial Spondyloarthritis Therapeutic Market

19. Italy Non-Radiographic Axial Spondyloarthritis Therapeutic Market

20. Spain Non-Radiographic Axial Spondyloarthritis Therapeutic Market

21. Eastern Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market

22. Russia Non-Radiographic Axial Spondyloarthritis Therapeutic Market

23. North America Non-Radiographic Axial Spondyloarthritis Therapeutic Market

24. USA Non-Radiographic Axial Spondyloarthritis Therapeutic Market

25. Canada Non-Radiographic Axial Spondyloarthritis Therapeutic Market

26. South America Non-Radiographic Axial Spondyloarthritis Therapeutic Market

27. Brazil Non-Radiographic Axial Spondyloarthritis Therapeutic Market

28. Middle East Non-Radiographic Axial Spondyloarthritis Therapeutic Market

29. Africa Non-Radiographic Axial Spondyloarthritis Therapeutic Market

30. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Competitive Landscape And Company Profiles

31. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Other Major And Innovative Companies

32. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market

34. Recent Developments In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market

35. Non-Radiographic Axial Spondyloarthritis Therapeutic Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기